Amyotrophic Lateral Sclerosis & The Endocannabinoid System


Amyotrophic Lateral Sclerosis – ALS a fatal motor neuron disorder, which is characterized by progressive loss of the upper and lower neurons at the spinal or bulbar level (Zerei, S. et al., 2015).

Various studies have shown that ECS can be beneficial in regulating ALS as it reduces the excitotoxic and oxidative damage.

Bilsland and Greensmith (2008) note that cannabinoids exert anti-glutamatergic and anti-inflammatory actions through activation of the CB receptors. The stimulation of the CB1 may, therefore, inhibit glutamate release from presynaptic nerve terminals and reduce the postsynaptic calcium influx in response to the glutamate stimulation. Finally, cannabinoids agents may also exert anti-oxidant actions by a receptor-independent mechanism. In this case, the capacity for the cannabinoids to target multiple neurotoxic pathways in various cell populations may increase their possible treatment of ALS.


Amyotrophic Lateral Sclerosis & The Endocannabinoid System

Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P. F. Chinea, A. (2015). A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology International, 6, 171.
Bilsland, L. & Greensmith, L. (2008).The ECS in amyotrophic lateral sclerosis. National Library Medicine, 14(23); 2306-16.